Amplification of HGF/Met axis to promote HCC cell proliferation and metastasis also renders Met as a therapeutic target in HCC [19,20], hence Met inhibitors such as foretinib and tivantinib were also applied in the treatment of HCC [5,19,26,29]. Here, HGF is linked to hepatocellular carcinoma.